Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial

R Ferla; P Claudiani; M Savarese; K Kozarsky; R Parini; M Scarpa; MA Donati; G Sorge; JJ Hopwood; G Parenti; S Fecarotta; V Nigro; HS Sivri; Ans van der Ploeg; G Andria; N Brunetti-Pierri; A Auricchio

doi:10.1089/hum.2014.109

Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial

R Ferla, P Claudiani, M Savarese, K Kozarsky, R Parini, M Scarpa, MA Donati, G Sorge, JJ Hopwood, G Parenti, S Fecarotta, V Nigro, HS Sivri, Ans van der Ploeg, G Andria, N Brunetti-Pierri, A Auricchio

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	145-152
Number of pages	8
Journal	Human Gene Therapy
Volume	26
Issue number	3
DOIs	https://doi.org/10.1089/hum.2014.109
Publication status	Published - 2015

Access to Document

10.1089/hum.2014.109

Cite this

Ferla, R., Claudiani, P., Savarese, M., Kozarsky, K., Parini, R., Scarpa, M., Donati, MA., Sorge, G., Hopwood, JJ., Parenti, G., Fecarotta, S., Nigro, V., Sivri, HS., van der Ploeg, A., Andria, G., Brunetti-Pierri, N., & Auricchio, A. (2015). Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial. Human Gene Therapy, 26(3), 145-152. https://doi.org/10.1089/hum.2014.109

@article{794b8bfb79a54b36936cf63cf7897704,

title = "Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial",

author = "R Ferla and P Claudiani and M Savarese and K Kozarsky and R Parini and M Scarpa and MA Donati and G Sorge and JJ Hopwood and G Parenti and S Fecarotta and V Nigro and HS Sivri and {van der Ploeg}, Ans and G Andria and N Brunetti-Pierri and A Auricchio",

year = "2015",

doi = "10.1089/hum.2014.109",

language = "Undefined/Unknown",

volume = "26",

pages = "145--152",

journal = "Human Gene Therapy",

issn = "1043-0342",

publisher = "Mary Ann Liebert Inc.",

number = "3",

}

Ferla, R, Claudiani, P, Savarese, M, Kozarsky, K, Parini, R, Scarpa, M, Donati, MA, Sorge, G, Hopwood, JJ, Parenti, G, Fecarotta, S, Nigro, V, Sivri, HS, van der Ploeg, A, Andria, G, Brunetti-Pierri, N & Auricchio, A 2015, 'Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial', Human Gene Therapy, vol. 26, no. 3, pp. 145-152. https://doi.org/10.1089/hum.2014.109

Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial. / Ferla, R; Claudiani, P; Savarese, M et al.

In: Human Gene Therapy, Vol. 26, No. 3, 2015, p. 145-152.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Prevalence of Anti-Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial

AU - Ferla, R

AU - Claudiani, P

AU - Savarese, M

AU - Kozarsky, K

AU - Parini, R

AU - Scarpa, M

AU - Donati, MA

AU - Sorge, G

AU - Hopwood, JJ

AU - Parenti, G

AU - Fecarotta, S

AU - Nigro, V

AU - Sivri, HS

AU - van der Ploeg, Ans

AU - Andria, G

AU - Brunetti-Pierri, N

AU - Auricchio, A

PY - 2015

Y1 - 2015

U2 - 10.1089/hum.2014.109

DO - 10.1089/hum.2014.109

M3 - Article

SN - 1043-0342

VL - 26

SP - 145

EP - 152

JO - Human Gene Therapy

JF - Human Gene Therapy

IS - 3

ER -